Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of common stock, $0.00001 par value (the "Common Stock") of Aclaris Therapeutics, Inc. (the "Issuer") held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage of class is based on 139,663,680 shares of Common Stock outstanding as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 7, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage of class is based on 139,663,680 shares of Common Stock outstanding as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on May 7, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage of class is based on 139,663,680 shares of Common Stock outstanding as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on May 7, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percentage of class is based on 139,663,680 shares of Common Stock outstanding as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on May 7, 2026.


SCHEDULE 13G



 
Vivo Opportunity Fund Holdings, L.P.
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:05/12/2026
 
Vivo Opportunity, LLC
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:05/12/2026
 
Vivo Opportunity Cayman Fund, L.P.
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
Date:05/12/2026
 
Vivo Opportunity Cayman, LLC
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:05/12/2026